title: [Intravenous thrombolysis patients with acute ischemic stroke: the analysis of the 100 cases. Part I. Characteristic of the patients and effectiveness of treatment].
abstract: BACKGROUND
  Intravenous thrombolytic therapy with recombinant tissue activator (rt-PA) in treating acute ischemic stroke is effective and safe in the time window 4.5 hours after symptom onset.
  
  
  METHODS
  In the study group of patients demographic and logistic data and vascular risk factors were analysed. We also analysed status of the patients at the moment of admission, after 24 hours, one month and 3 months after symptom onset according to National Institutes of Health Stroke Scale (NIHSS) and results of treatment after 3 months according to modified Rankin Score (mRS). We compared the selective variables with data from the register SITS.
  
  
  RESULTS
  Between September 2006 and April 2009 in the stroke unit in Sandomierz 807 patients with ischemic stroke were treated, including 100 patients (aged 42-88, mean 69.74 +/- 9.85; 55% of men) treated with rt-PA (12.39%). In 22% of patients treated rt-PA large and medium vessel disease, in 47%--cardiogenic embolism, in 4%--small vessel disease, in 3%-- other unusual causes and in 24%--infarct multiple etiology were diagnosed. The average time from the onset of the disease to the beginning of the treatment was 148.25 +/- 38.77 min. (in SITS centers--145 min.). At the moment of admission the average neurological conditions in NIHSS 12.03 +/- 4.94 (SITS--12); after 24 hours--8.51 +/- 6.09; after 7 days--6.51 +/- 6.38; after one month--4.27 +/- 5.15 and after 3 months--2.95 +/- 3.36 were evaluated. The results according to mRS were respectively: after 7 days--2.80 +/- 1.77; after 1 month--2.37 +/- 2.00 and after 3 months 2.16 +/- 2.16(SITS--2.5). After 3 months 53% of patients were functionally independent (SITS--53%), 29%--had moderate or severe disability (-32%) and 18%--died (-15%).
  
  
  CONCLUSIONS
  In analysed time in stroke unit in Sandomierz the percentage of patients with acute ischemic stroke treated with rt-PA was high. The presentation of results of intravenous thrombolysis in patients with acute ischemic stroke performed in different centers makes the important aspect of evaluation of the effectiveness and safety of this therapy.
authors.affiliation: Sandomierski Ośrodek Neurologii z Oddziałem Neurologii i Oddziałem Udarowym SPZZOZ w Sandomierzu. piotrsobolewski@poczta.onet.pl
authors.forename: Piotr
authors.initials: P
authors.lastname: Sobolewski
authors.forename: Monika
authors.initials: M
authors.lastname: Sledzińska
authors.forename: Wiktor
authors.initials: W
authors.lastname: Szczuchniak
authors.forename: Renata
authors.initials: R
authors.lastname: Hatalska-Zerebiec
authors.forename: Marcin
authors.initials: M
authors.lastname: Grzesik
authors.forename: Anna
authors.initials: A
authors.lastname: Sobota
mesh_terms: D061605:Administration, Intravenous; D000328:Adult; D000368:Aged; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D012307:Risk Factors; D015996:Survival Rate; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator